Results from the Belgian mantle cell lymphoma registry

Acta Clin Belg. 2017 Jun;72(3):172-178. doi: 10.1080/17843286.2017.1293328. Epub 2017 Feb 22.

Abstract

Introduction: Mantle cell lymphoma is a B-cell non-Hodgkin's lymphoma characterized by a t(11;14), resulting in overexpression of cyclin D1. Conventional chemotherapy obtains frequent (but short) remissions, leading to a poor median overall survival (OS) of 3-5 years. To obtain more information about the prevalence and current treatment of Mantle cell lymphoma (MCL) in Belgium, we collected data in a Belgian registry of MCL.

Materials and methods: All Belgian MCL patients, t(11;14) and/or cyclin D1 positive, seen in hematology departments over a one-year period (April 2013-March 2014) were included. Data about patient characteristics, histology, treatment lines, and response were compiled and retrospectively analyzed.

Results: Four hundred and four patients were included with a median age at diagnosis of 64 years (range 23-96 years) and a male predominance (72%). For 2013, we calculated a prevalence of at least 36.2 per million and an incidence of at least 7.0 per million in the Belgian population. Characteristics at diagnosis involved lymphadenopathy (82%), splenomegaly (44%), B-symptoms (39%), and hepatomegaly (10%). Bone marrow invasion was present at diagnosis in 77%. Stage at diagnosis was advanced in the majority of cases. The median number of treatment lines was 1. Type of first line treatment included a combination of anthracyclin and cytarabine-based regimen (34%), anthracyclin (39%), and other. Rituximab was used in 88% of first line treatments. In 44% first line treatment was followed by autologous stem cell transplantation.

Conclusion: The analysis of this Belgian MCL registry provides insight in the epidemiology, demographics, and current treatment of our Belgian MCL population.

Keywords: Demographics; Epidemiology; Mantle cell lymphoma; Registry; Treatment.

MeSH terms

  • Adult
  • Aged
  • Aged, 80 and over
  • Anthracyclines / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Belgium
  • Cytarabine / administration & dosage
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Hepatomegaly / etiology
  • Humans
  • Lymphadenopathy / etiology
  • Lymphoma, Mantle-Cell / complications
  • Lymphoma, Mantle-Cell / pathology
  • Lymphoma, Mantle-Cell / therapy*
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Registries*
  • Retrospective Studies
  • Rituximab / administration & dosage
  • Splenomegaly / etiology
  • Transplantation, Autologous
  • Young Adult

Substances

  • Anthracyclines
  • Cytarabine
  • Rituximab